Much has been written recently about Puerto Rico’s role in the reshoring movement. The conversation is both necessary and timely. As the world’s supply chains are being rewritten, Puerto Rico, as part of the United States, stands uniquely positioned to play a leading role in this transformation.
As the global economy recalibrates, Puerto Rico is once again at the heart of a new manufacturing map defined by trust, quality, and reliability.
In this new era, reshoring is more than a logistics trend; it is a strategic realignment. For the bioscience industry, it means securing the supply of life-saving medicines and devices closer to home. For Puerto Rico, it represents an opportunity to leverage decades of manufacturing excellence, world-class infrastructure, and a skilled, bilingual workforce to strengthen U.S. production capacity and global competitiveness.
That opportunity is already taking shape. This year alone, global leaders such as Eli Lilly, Amgen, Coopervision, Terumo, Millicent Pharma, AstraZeneca, and others have announced expansions totaling more than $2 billion in new investment and over 4,000 jobs. This is just the beginning.
This wave of new activity underscores Puerto Rico’s central role in the United States’ bioscience ecosystem. It is worth noting that these are not short-term expansions; they are long-term commitments that reflect confidence in Puerto Rico’s people, infrastructure, and strategic value. More importantly, while we continue to modernize critical infrastructure and streamline processes, these investments demonstrate that the private sector already recognizes Puerto Rico’s global status and long-term potential.
At Invest Puerto Rico, we have been championing reshoring since 2020 as a key opportunity to attract high-value manufacturing back to the United States. We are strategically positioning Puerto Rico on the global reshoring map through targeted commercial missions, fam tours, international conferences, and sector-specific promotion. From SelectUSA to BIO International and MedTech, our team is proactively engaging companies evaluating U.S. jurisdictions for their next phase of growth.
Beyond this, what sets Puerto Rico apart for reshoring is our talent and legacy. Our workforce combines technical proficiency with bilingual communication and regulatory know-how. More than 50% of university graduates specialize in STEM or health-related fields, and the island hosts over 120 FDA-approved facilities that collectively export $53 billion in bioscience products annually, including five of the world’s top 20 best-selling medicines.
Reshoring takes time. Realigning global supply chains and establishing new facilities is a multi-year process, but momentum is already underway. Puerto Rico’s value proposition continues to resonate with companies seeking not only operational efficiency, but also reliability, innovation, and resilience.
Each new expansion represents more than just capital investment; it is a vote of confidence in Puerto Rico’s ability to deliver, adapt, and lead. The global reshoring movement is not a race with a single winner. It is a long-term shift that rewards jurisdictions that innovate, collaborate, and deliver consistency. Puerto Rico is doing exactly that.
Puerto Rico is ready to power the future of biosciences.
